Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: An open prospective study

Journal of Clinical Psychiatry

Volumn 57, Issue 10, 1996, Pages 460-466

  Smith, Robert C ^a,b,c   Chua, Jayson W ^b   Lipetsker, Boris ^b   Bhattacharyya, Anjan ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MANHATTAN PSYCHIATRIC CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; LITHIUM; NEUROLEPTIC AGENT; RISPERIDONE; VALPROIC ACID;

ADULT; AGITATION; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM;

EID: 0029811287     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v57n1004     Document Type: Article

References (18)

1. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;115:825-835
2. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacology 1993;13:25-40
3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
4. Meltzer HY. Dimensions of clozapine response. Br J Psychiatry 1992;160 (suppl 17):46-53
5. Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant schizophrenic patients, I: preliminary findings. Psychopharmacology (Berl) 1989;99(suppl):S68-S72
6. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
7. Andreasen NC. The Scale for the Assessment of Positive Symptoms in Schizophrenia (SAPS). Iowa City, Iowa: University of Iowa; 1984
8. Andreasen NC. The Scale for the Assessment of Negative Symptoms in Schizophrenia (SANS). Iowa City, Iowa: University of Iowa; 1983
9. Thompson PA, Buckley PF, Meltzer HY. The Brief Psychiatric Rating Scale: effect of scaling system on clinical response assessment. J Clin Psychopharmacol 1994;14:344-346
10. Smith RC. Lower dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients [letter]. Arch Gen Psychiatry 1994;31: 427-429
11. Klieser E, Lehmann E, Kinzler E, et al. Randomized, double-blind controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995;15(suppl 1):45S-51S
12. Daniel D, Goldberg T, Weinberger D, et al. Cross-over comparison of risperidone and clozapine on clinical, cognitive and side effect measures in treatment-resistant psychosis. Presented at the 34th New Clinical Drug Evaluation Unit meeting; June 1994; Marco Island, Fla
13. Claus A, Bollen J, De-Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305
14. Schooler NR. Negative symptoms in schizophrenia: assessment of the effect of risperidone. J Clin Psychiatry 1994;55(5, suppl):22-28
15. Wilms G, Van Onbgeval C, Baert AL, et al. Ventricular enlargement, clinical correlations and treatment outcomes in chronic schizophrenic inpatients. Acta Psychiatr Scand 1992;85:306-312
16. Muller-Span F, the International Risperidone Research Group. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol 1992;15(suppl 1):90A-91A
17. Carpenter WT. Serotonin-dopamine antagonists and treatment of negative symptoms. J Clin Psychopharmacol 1995;15(suppl 1):30S-35S
18. Carpenter WT, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145: 578-583